Focus on Target Selection

The potential for targeted protein degradation (TPD) is vast. At C4 Therapeutics, our industry-leading science, which includes a proprietary Cereblon Toolkit and capabilities to develop both MonoDAC™ degraders (commonly called molecular glues) and BiDAC™ degraders (referred to as heterobifunctional degraders), greatly expands the landscape of targets we can pursue.

However, we are strategic in the disease-causing proteins we target. We focus our internal pipeline on oncology targets that we believe could benefit from a TPD approach. Through our target identification process, we evaluate where TPD could have an outsized patient impact, either by its potential to improve upon existing treatment options or provide new treatments for diseases that currently have no approved therapies.

When considering what targets to select for research activities, biology plays an important role. We select targets with a clear genetic link to a disease. We also consider how a degrader could offer a benefit over an inhibitor or other therapeutic option.

We also consider clinical development as part of the target selection process. We review potential targets to ensure we can prospectively select patients for clinical trials and can identify a path to registration. We also evaluate available biomarker assays to help us identify which patients may benefit from the investigational therapy.